Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: August 2008
-
By Kevin E. Noonan — James Surowiecki is exercising his antipatent animus once again in the August 11th edition of The New Yorker. Mr. Surowiecki (at right) writes a weekly column called "The Financial Page" in the magazine, and he has shown that he doesn’t like patents several times in his work. These…
-
By Kevin E. Noonan — EvaluatePharma, a London-based company providing forecasting and industry analysis to the biotech and pharma sector, released a report today predicting the big pharma landscape in 2014, based on industry trends, current and prospective drug pipelines, acquisitions and partnering and the predicted "patent cliff" that will occur as blockbuster…
-
By Christopher P. Singer — In a Notice published in the Federal Register (73 Fed. Reg. 45662) on August 6, 2008, the U.S. Patent and Trademark Office proposes new rules that severely limit the types of papers that can be submitted to the Office by facsimile. Essentially, the USPTO proposes to amend the…
-
By Donald Zuhn — Last week, the Public Patent Foundation (PUBPAT) announced that a coalition of consumer advocacy and public interest groups had filed an amici brief in the Tafas v. Dudas appeal. The brief, which was signed by PUBPAT Executive Director Dan Ravicher (below left), was filed on behalf of PUBPAT, AARP,…
-
Patent Docs provides two reviews for the price of one as Kevin Noonan and Donald Zuhn each discuss the second edition of Martin Voet’s book "The Generic Challenge: Understanding Patents, FDA & Pharmaceutical Life-Cycle Management." By Kevin Noonan — Martin A. Voet, Senior Vice President and Chief Intellectual Property Counsel at Allergan, Inc.,…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Sepracor Inc. et al. v. Barr Pharmaceuticals, Inc. et al.5:08-cv-00362; filed July 30, 2008 in the Eastern District of North Carolina Infringement…
-
August 5, 2008 – Intellectual Property Due Diligence and Audit Bootcamp (West Legalworks) – 1:00-2:00 PM (EDT) August 11-12, 2008 – Advanced Patent Prosecution Workshop 2008: Claim Drafting & Amendment Writing (Practising Law Institute) – San Francisco, CA August 10-15, 2008 – Advanced Courses (Patent Resources Group) – Washington, DC September 11, 2008 – Developments…
-
By Sherri Oslick — Earlier this week the litigation between Teva Pharmaceutical Industries Ltd. and Dr. Reddy’s Laboratories Inc. over generic Coreg® was dismissed without costs and without prejudice based on a settlement between the parties. As we reported previously, the suit was originally filed in the District Court of New Jersey on…
-
By Christopher P. Singer — The U.S. Patent and Trademark Office sent out an e-Commerce update on July 31, 2008, notifying EFS users of enhancements that will be introduced with EFS-Web 1.4 (to be released on August 17, 2008). For one, users will be able to launch their e-mail programs in EFS-Web and…
-
West Legalworks will be offering an "Intellectual Property Due Diligence and Audit Bootcamp" audio webcast on August 5, 2008 from 1:00-2:00 PM (EDT). Lisa Brownlee, author of Intellectual Property Due Diligence in Corporate Transactions: Investment, Risk Assessment and Management, will provide an overview of the IP due diligence process, from the memorandum of understanding/letter of…
Patent Docs 